StreetInsider.com News Articles

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 09 Mar 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of (i) options to purchase an aggregate of 134,540 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in Definium common shares upon vesting, with effective grant dates of February 24, 2026, February

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 09 Mar 2026 16:01:00 -0400

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 09 Mar 2026 16:01:00 -0400

Definium Therapeutics Announces New Employee Inducement Grants

Mon, 09 Mar 2026 16:01:00 -0400

Form 10-K Definium Therapeutics, For: Dec 31

Thu, 26 Feb 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260226/26071359.html

Form 10-K Definium Therapeutics, For: Dec 31

Thu, 26 Feb 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260226/26071359.html

Form 8-K Definium Therapeutics, For: Feb 26

Thu, 26 Feb 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260226/26070901.html

Form 8-K Definium Therapeutics, For: Feb 26

Thu, 26 Feb 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260226/26070901.html

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Thu, 26 Feb 2026 16:01:00 -0400

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026

Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026

Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026

$411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028

Conference call scheduled today at 4:30 p.m. EST

Wolfe Research Starts Definium Therapeutics Inc (DFTX) at Outperform, Top Pick

Tue, 24 Feb 2026 09:19:08 -0400

(Updated - February 24, 2026 9:19 AM EST)

Wolfe Research analyst Rudy Li initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Outperform rating and a price target of $25.00.

The analyst comments "MoA: DT120 is proprietary formulation of lysergide (LSD) D-tartrate, a potent psychedelic product targeting 5-HT2A and downstream neuronal connectivity ➢ Indications: GAD and MDD ➢ Key differentiator: ➢ 1 single dose (oral) for a treatment period of 8 hours in centers (likely only 2-4 times a year) ➢ Rapid onset (Day 1), large effect size (2x vs SOCs), high responder/remission rates (~50%) and long duration (>12 weeks) ➢

Wolfe Research Starts Definium Therapeutics Inc (DFTX) at Outperform, Top Pick

Tue, 24 Feb 2026 09:19:08 -0400

(Updated - February 24, 2026 9:19 AM EST)

Wolfe Research analyst Rudy Li initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Outperform rating and a price target of $25.00.

Wolfe Research Starts Definium Therapeutics Inc (DFTX) at Outperform, Top Pick

Tue, 24 Feb 2026 09:19:08 -0400

(Updated - February 24, 2026 9:19 AM EST)

Wolfe Research analyst Rudy Li initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Outperform rating and a price target of $25.00.

Wolfe Research Starts Definium Therapeutics Inc (DFTX) at Outperform, Top Pick

Tue, 24 Feb 2026 09:19:08 -0400

(Updated - February 24, 2026 9:19 AM EST)

Wolfe Research analyst Rudy Li initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Outperform rating and a price target of $25.00.

Definium Therapeutics to Participate at Upcoming Investor Conferences

Tue, 24 Feb 2026 07:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference
- Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET
- Location: Boston, MA
- Webcast Link: TD Cowen 46th Annual Health Care Conference
Jefferies Biotech on the Beach Summit
- Date: Tuesday, March 10, 2026
- Location: Miami Beach, FL
Leerink Partners

Definium Therapeutics to Participate at Upcoming Investor Conferences

Tue, 24 Feb 2026 07:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference

Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET

Location: Boston, MA

Webcast Link: TD Cowen 46th Annual Health Care Conference

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink Partners

Definium Therapeutics to Participate at Upcoming Investor Conferences

Tue, 24 Feb 2026 07:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference

Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET

Location: Boston, MA

Webcast Link: TD Cowen 46th Annual Health Care Conference

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink Partners

Definium Therapeutics to Participate at Upcoming Investor Conferences

Tue, 24 Feb 2026 07:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference

Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET

Location: Boston, MA

Webcast Link: TD Cowen 46th Annual Health Care Conference

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink Partners

Definium Therapeutics to Participate at Upcoming Investor Conferences

Tue, 24 Feb 2026 07:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference

Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET

Location: Boston, MA

Webcast Link: TD Cowen 46th Annual Health Care Conference

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink Partners